Tag Archives: CANSINOBIO COVID-19 VACCINE

CanSinoBIO’s single-dose COVID-19 vaccine, given at a lower dosage than that for adults, is safe and triggers an immune response in children aged 6-17, results from a small trial showed. Researchers decided to lower the dosage after a few participants developed fever and headaches graded at level 2 severity – the second-lowest of four levels. In children, the lower dose …

Read More »